CEO: Mary Kerr

Advent Contact: Kaasim Mahmood/Raj Parekh

Novel neurokinin antagonists

NeRRe was created to develop a portfolio of four clinical and pre-clinical neurokinin (NK) receptor antagonists in-licensed from GSK, a dual NK-1, 3 antagonist and three NK-1 antagonists. The neurokinin axis is now implicated in a range of disorders including post-menopausal vasomotor symptoms, chronic persistent refractory cough and addiction. .

Advent founded NeRRe in 2012. NeRRe completed a £23M private financing in 2016.


NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round